• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

透明细胞肾细胞癌的肿瘤免疫微环境。

The Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma.

机构信息

Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, 2635 Laurel Street, Vancouver, BC V6H 3Z6, Canada.

Division of Infectious Diseases, Department of Medicine, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada.

出版信息

Int J Mol Sci. 2023 Apr 27;24(9):7946. doi: 10.3390/ijms24097946.

DOI:10.3390/ijms24097946
PMID:37175653
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10178526/
Abstract

Clear cell renal cell carcinoma (ccRCC) is a type of kidney cancer that arises from the cells lining the tubes of the kidney. The tumor immune microenvironment (TIME) of ccRCC is a complex interplay of various immune cells, cytokines, and signaling pathways. One of the critical features of the ccRCC TIME is the presence of infiltrating immune cells, including T cells, B cells, natural killer cells, dendritic cells, and myeloid-derived suppressor cells. Among these cells, CD8+ T cells are particularly important in controlling tumor growth by recognizing and killing cancer cells. However, the TIME of ccRCC is also characterized by an immunosuppressive environment that hinders the function of immune cells. Several mechanisms contribute to the immunosuppressive nature of the ccRCC TIME. For instance, ccRCC cells produce cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), which suppress immune cell activation and promote the differentiation of regulatory T cells (Tregs). Tregs, in turn, dampen the activity of effector T cells and promote tumor growth. In addition, ccRCC cells can express programmed death-ligand 1 (PD-L1), which interacts with the programmed cell death protein 1 (PD-1) receptor on T cells to inhibit their function. In addition, other immune checkpoint proteins, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and lymphocyte activation gene 3 (), also contribute to the immunosuppressive milieu of the ccRCC TIME. Finally, the hypoxic and nutrient-poor microenvironment of ccRCC can stimulate the production of immunosuppressive metabolites, such as adenosine and kynurenine, which further impair the function of immune cells. Understanding the complex interplay between tumor cells and the immune system in the ccRCC TIME is crucial for developing effective immunotherapies to treat this disease.

摘要

透明细胞肾细胞癌(ccRCC)是一种起源于肾脏管状细胞的肾癌。ccRCC 的肿瘤免疫微环境(TIME)是各种免疫细胞、细胞因子和信号通路复杂相互作用的结果。ccRCC TIME 的一个关键特征是存在浸润免疫细胞,包括 T 细胞、B 细胞、自然杀伤细胞、树突状细胞和髓系来源的抑制细胞。在这些细胞中,CD8+T 细胞通过识别和杀死癌细胞在控制肿瘤生长方面尤为重要。然而,ccRCC 的 TIME 也具有抑制性免疫环境,这会阻碍免疫细胞的功能。几种机制导致了 ccRCC TIME 的免疫抑制特性。例如,ccRCC 细胞产生细胞因子,如白细胞介素 10(IL-10)和转化生长因子-β(TGF-β),它们抑制免疫细胞的激活并促进调节性 T 细胞(Tregs)的分化。Tregs 反过来又抑制效应 T 细胞的活性并促进肿瘤生长。此外,ccRCC 细胞可以表达程序性死亡配体 1(PD-L1),它与 T 细胞上的程序性死亡蛋白 1(PD-1)受体相互作用,抑制其功能。此外,其他免疫检查点蛋白,如细胞毒性 T 淋巴细胞相关蛋白 4(CTLA-4)和淋巴细胞激活基因 3(),也有助于 ccRCC TIME 的免疫抑制环境。最后,ccRCC 的低氧和营养贫乏的微环境可以刺激免疫抑制代谢物的产生,如腺苷和犬尿氨酸,这进一步损害免疫细胞的功能。了解肿瘤细胞与 ccRCC TIME 中免疫系统之间的复杂相互作用对于开发有效的免疫疗法来治疗这种疾病至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b33/10178526/19aaca65b83c/ijms-24-07946-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b33/10178526/7cd16b047103/ijms-24-07946-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b33/10178526/dc0003f7fadc/ijms-24-07946-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b33/10178526/19aaca65b83c/ijms-24-07946-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b33/10178526/7cd16b047103/ijms-24-07946-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b33/10178526/dc0003f7fadc/ijms-24-07946-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b33/10178526/19aaca65b83c/ijms-24-07946-g003.jpg

相似文献

1
The Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma.透明细胞肾细胞癌的肿瘤免疫微环境。
Int J Mol Sci. 2023 Apr 27;24(9):7946. doi: 10.3390/ijms24097946.
2
Intratumoral CXCL13CD8T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma.肿瘤内 CXCL13CD8T 细胞浸润决定了透明细胞肾细胞癌患者的不良临床结局和免疫逃避结构。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001823.
3
Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.肾细胞癌伴肉瘤样去分化患者的程序性细胞死亡配体1及肿瘤浸润淋巴细胞状态
Cancer. 2017 Dec 15;123(24):4823-4831. doi: 10.1002/cncr.30937. Epub 2017 Aug 22.
4
Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion.肿瘤相关巨噬细胞衍生的白细胞介素-23 将肾癌的谷氨酰胺成瘾与免疫逃避联系起来。
Eur Urol. 2019 May;75(5):752-763. doi: 10.1016/j.eururo.2018.09.030. Epub 2018 Oct 4.
5
Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer.原发性和转移性肾细胞癌微环境中免疫检查点的调控及其预后意义。
Clin Cancer Res. 2015 Jul 1;21(13):3031-40. doi: 10.1158/1078-0432.CCR-14-2926. Epub 2015 Feb 16.
6
VSIG4 induces the immunosuppressive microenvironment by promoting the infiltration of M2 macrophage and Tregs in clear cell renal cell carcinoma.VSIG4 通过促进 M2 巨噬细胞和 Tregs 在透明细胞肾细胞癌中的浸润来诱导免疫抑制微环境。
Int Immunopharmacol. 2024 Dec 5;142(Pt A):113105. doi: 10.1016/j.intimp.2024.113105. Epub 2024 Sep 10.
7
STING agonist, SMA-2, inhibits clear cell renal cell carcinoma through improving tumor microenvironment.STING激动剂SMA-2通过改善肿瘤微环境抑制肾透明细胞癌。
Mol Cell Biochem. 2024 Jul;479(7):1697-1705. doi: 10.1007/s11010-024-04970-w. Epub 2024 Apr 9.
8
Endosialin-positive tumor-derived pericytes promote tumor progression through impeding the infiltration of CD8 T cells in clear cell renal cell carcinoma.内皮细胞黏附分子阳性肿瘤衍生周细胞通过阻碍 CD8 T 细胞浸润促进肾透明细胞癌的进展。
Cancer Immunol Immunother. 2023 Jun;72(6):1739-1750. doi: 10.1007/s00262-023-03372-z. Epub 2023 Jan 16.
9
Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma.肿瘤相关巨噬细胞衍生趋化因子 CCL5 促进透明细胞肾细胞癌的进展和免疫抑制性肿瘤微环境。
Int J Biol Sci. 2022 Jul 18;18(13):4884-4900. doi: 10.7150/ijbs.74647. eCollection 2022.
10
NKG2ACD8 T cells infiltration determines immunosuppressive contexture and inferior response to immunotherapy in clear cell renal cell carcinoma.NKG2ACD8+T 细胞浸润决定了透明细胞肾细胞癌的免疫抑制微环境和对免疫治疗的反应不良。
J Immunother Cancer. 2024 Jan 23;12(1):e008368. doi: 10.1136/jitc-2023-008368.

引用本文的文献

1
Characteristics of the tumor microenvironment and potential immunotherapy strategies in renal cell carcinoma.肾细胞癌中肿瘤微环境的特征及潜在免疫治疗策略
Front Immunol. 2025 Sep 2;16:1643533. doi: 10.3389/fimmu.2025.1643533. eCollection 2025.
2
Immunotherapy Resistance and Therapeutic Strategies in PD-L1 High Expression Non-Small Cell Lung Cancer.PD-L1高表达非小细胞肺癌中的免疫治疗耐药性及治疗策略
Onco Targets Ther. 2025 Aug 29;18:953-966. doi: 10.2147/OTT.S539978. eCollection 2025.
3
GGTLC1 Is a Prognostic Biomarker in Renal Clear Cell Carcinoma.

本文引用的文献

1
Combination of an autophagy inhibitor with immunoadjuvants and an anti-PD-L1 antibody in multifunctional nanoparticles for enhanced breast cancer immunotherapy.多功能纳米载药系统中联合自噬抑制剂、免疫佐剂和抗 PD-L1 抗体用于增强乳腺癌免疫治疗。
BMC Med. 2022 Oct 28;20(1):411. doi: 10.1186/s12916-022-02614-8.
2
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.评估转移性肾细胞癌的肿瘤微环境和免疫检查点抑制剂反应的生物标志物。
J Immunother Cancer. 2022 Oct;10(10). doi: 10.1136/jitc-2022-005249.
3
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
GGTLC1是肾透明细胞癌的一种预后生物标志物。
Int J Genomics. 2025 Aug 12;2025:7524935. doi: 10.1155/ijog/7524935. eCollection 2025.
4
Metabolic reprogramming of arachidonic acid in clear cell renal carcinoma promotes an immunosuppressive microenvironment by activating MDK signaling pathway.透明细胞肾细胞癌中花生四烯酸的代谢重编程通过激活MDK信号通路促进免疫抑制微环境。
Clin Exp Med. 2025 Aug 13;25(1):291. doi: 10.1007/s10238-025-01807-8.
5
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.帕博利珠单抗联合阿昔替尼与舒尼替尼治疗晚期透明细胞肾细胞癌:3期KEYNOTE-426试验的5年生存率及生物标志物分析
Nat Med. 2025 Aug 1. doi: 10.1038/s41591-025-03867-5.
6
A systematic review of the latest progress of drug resistance and clinical application of immunotherapy in renal cell carcinoma in the past five years based on bibliometrics.基于文献计量学的过去五年肾细胞癌耐药性及免疫治疗临床应用最新进展的系统评价
Hum Vaccin Immunother. 2025 Dec;21(1):2532954. doi: 10.1080/21645515.2025.2532954. Epub 2025 Jul 16.
7
Advances in Genitourinary Tumor Genomics and Immunotherapy.泌尿生殖系统肿瘤基因组学与免疫治疗的进展
Genes (Basel). 2025 May 30;16(6):667. doi: 10.3390/genes16060667.
8
Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC).透明细胞肾细胞癌(ccRCC)中的免疫检查点抑制剂
Int J Mol Sci. 2025 Jun 11;26(12):5577. doi: 10.3390/ijms26125577.
9
Cancer-associated fibroblasts in clear cell renal cell carcinoma: functional heterogeneity, tumor microenvironment crosstalk, and therapeutic opportunities.透明细胞肾细胞癌中的癌症相关成纤维细胞:功能异质性、肿瘤微环境相互作用及治疗机会
Front Immunol. 2025 Jun 4;16:1617968. doi: 10.3389/fimmu.2025.1617968. eCollection 2025.
10
Identification of CENPW as a prognostic biomarker and potential therapeutic target for clear cell renal cell carcinoma.鉴定CENPW作为透明细胞肾细胞癌的预后生物标志物和潜在治疗靶点。
Discov Oncol. 2025 Jun 18;16(1):1138. doi: 10.1007/s12672-025-02859-8.
采用化疗和抗 PD-1 药物联合治疗作为一线治疗方案,为非鳞状非小细胞肺癌患者接种个体化新抗原疫苗 NEO-PV-01。
Cancer Cell. 2022 Sep 12;40(9):1010-1026.e11. doi: 10.1016/j.ccell.2022.08.003. Epub 2022 Aug 25.
4
Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy.用于肿瘤特异性蛋白降解和精准癌症治疗的工程化生物正交 POLY-PROTAC 纳米颗粒。
Nat Commun. 2022 Jul 26;13(1):4318. doi: 10.1038/s41467-022-32050-4.
5
Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells.免疫检查点阻断通过 PD-L1 增强了基于 CD28 的抗碳酸酐酶 IX 嵌合抗原受体 T 细胞,而不是基于 4-1BB 的抗碳酸酐酶 IX 嵌合抗原受体 T 细胞。
Int J Mol Sci. 2022 May 13;23(10):5448. doi: 10.3390/ijms23105448.
6
Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model.抗CAIX BBζ CAR4/8 T细胞在肾透明细胞癌小鼠模型中表现出卓越的疗效。
Mol Ther Oncolytics. 2021 Dec 31;24:385-399. doi: 10.1016/j.omto.2021.12.019. eCollection 2022 Mar 17.
7
Curcumin reverses the sunitinib resistance in clear cell renal cell carcinoma (ccRCC) through the induction of ferroptosis via the gene.姜黄素通过基因诱导铁死亡逆转透明细胞肾细胞癌(ccRCC)中的舒尼替尼耐药性。
Transl Cancer Res. 2021 Jul;10(7):3158-3167. doi: 10.21037/tcr-21-227.
8
Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma.去泛素化酶 OTUD6B 稳定突变型 pVHL,抑制肾透明细胞癌中的细胞迁移。
Cell Death Dis. 2022 Feb 2;13(2):97. doi: 10.1038/s41419-021-04135-3.
9
Hypoxia-Inducible Factor-2α as a Novel Target in Renal Cell Carcinoma.缺氧诱导因子-2α作为肾细胞癌的新靶点
J Kidney Cancer VHL. 2021 Apr 7;8(2):1-7. doi: 10.15586/jkcvhl.v8i1.170. eCollection 2021.
10
Cancer Associated Fibroblasts Promote Renal Cancer Progression Through a TDO/Kyn/AhR Dependent Signaling Pathway.癌症相关成纤维细胞通过TDO/犬尿氨酸/芳香烃受体依赖的信号通路促进肾癌进展。
Front Oncol. 2021 Mar 25;11:628821. doi: 10.3389/fonc.2021.628821. eCollection 2021.